CBD Combined With Essential Fatty Acids Is 40% More Efficient In Epilepsy Seizure Reduction Than Regular CBD, New Study
CBD Combined With Essential Fatty Acids Is 40% More Efficient In Epilepsy Seizure Reduction Than Regular CBD, New Study
CANAQUEST MEDICAL CORP (OTCPK:CANQF), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system, announced statistically significant efficacy results from the clinical dose and efficacy study conducted by Dr. W McIntyre Burnham, emeritus professor of the University of Toronto's Temerty Faculty of Medicine. In comparison to standard CBD, CQ-001 (cannabidiol "CBD" + IP formula - essential fatty acids) demonstrated 40% more seizure reduction at a medium dose in the maximal electroshock seizure model. This result indicates that CQ-001 is stronger than standard CBD, and could be used a lower dose to achieve seizure control.
運動醫療股份有限公司 (OTCPK:CANQF)是一家臨床階段生命科學公司,專注於藥物發現和開發用於中樞神經系統的下一代靶向大麻素治療藥物,宣布了由進行的臨床劑量和療效研究中具有統計學意義的療效結果 麥金泰爾伯納姆博士多倫多大學的 Temerty 醫學院榮休教授。 與標準中央商務區相比,CQ-001 (大麻二酚「CBD」+ IP 配方-必需脂肪酸) 40% 更多癲癇發作減少 在最大電擊癲癇發作模型中的中等劑量.該結果表明 CQ-001 比標準 CBD 更強,並且可以使用較低劑量來控制癲癇發作。
Highlights derived from the study are as follows:
從研究得出的亮點如下:
-
The enhanced efficacy from these clinical studies further validates the pre-clinical trial results obtained by Dr. Steven Laviolette, a professor and neuroscientist, at Western University.
-
These results set the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects and will define a dosage of CQ-001 for a clinical trial (phase II/III, double-blind trial, 60 patients).
-
CanaQuest has identified the regulatory pathways to obtain Rx drug identification numbers in Canada and the USA for epilepsy rare neurological conditions. CQ-001, in combination with its proprietary processing and delivery method, is estimated to be approved in about 3 years.
-
這些臨床研究的增強功效進一步驗證了以下方法獲得的臨床前試驗結果: 史蒂芬·拉維奧萊特博士西方大學教授和神經科學家
-
這些結果為實質上較小的 CBD 劑量設置了階段,從而產生預期的結果而沒有負面副作用,並將定義用於臨床試驗的 CQ-001 劑量(II/III 期,雙盲試驗,60 名患者)。
-
CanaCaCest 已確定了在加拿大和美國獲得 Rx 藥物識別號碼以治療癲癇罕見神經系統疾病的監管途徑。CQ-001 與其專有的加工和交付方法相結合,估計將在大約 3 年內獲得批准。
"Further testing will be necessary, however preliminary tests suggest that CQ-001 is stronger than regular CBD," stated Burnham, pharmacologist and co-director of EpLink.
「進一步的測試將是必要的, 但是初步測試表明,CQ-001 比常規 CBD 更強,」伯納姆說, 藥理學家和聯席主任 電子鏈接。
Paul Ramsay, president, stated, "The clinical study results reconfirm the pre-clinical trial results conducted at Western University, and further substantiate the magnitude of this life-changing discovery."
保罗·拉姆齐主席表示:「臨床研究結果再次確認了西方大學進行的臨床前試驗結果,並進一步證實了這一改變生活的發現的規模。」
Get your daily dose of cannabis news on Benzinga Cannabis. Don't miss out on any important developments in the industry.
獲取您每日劑量的大麻新聞 在苯甲大麻.不要錯過行業中的任何重要發展。
Photo by Jeff W on Unsplash
照片由傑夫 W 在未飛濺
譯文內容由第三人軟體翻譯。